N. Shah

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J. Berlin, A. Bardia, D. Juric, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J. Berlin, A. Bardia, D. Juric, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current management of mTOR inhibitor-associated stomatitis

N. Shah, 2015 .

Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy

P. Kelly, J. Rineer, Zhenjun Ma, 2017, International journal of breast cancer.

Chapter 91 – Target Blood Pressure in Hypertension Treatment: The J-shaped Curve Controversy

C. Lang, N. Shah, 2007 .

MGMT Inhibition Restores ERα Functional Sensitivity to Antiestrogen Therapy

K. Srivenugopal, S. Konduri, C. Baker, 2012, Molecular medicine.

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases

D. Hayes, C. Miller, J. Parker, 2018, Breast Cancer Research and Treatment.

Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer

A. Bardia, H. Rugo, J. Diamond, 2019, The New England journal of medicine.

Lifestyle Interventions in the Prevention and Treatment of Cancer

J. Hajdenberg, N. Shah, G. Pennock, 2009 .

A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases.

Jenny C. Chang, M. Cristofanilli, B. Jovanovic, 2022, Clinical breast cancer.